Search

REVOLUTION Medicines Inc

Cerrado

SectorSanidad

203.4 -0.94

Resumen

Variación precio

24h

Actual

Mínimo

199.66

Máximo

206.37

Métricas clave

By Trading Economics

Ingresos

-644M

-1.1B

BPA

-2.34

Empleados

883

EBITDA

-184M

-621M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+23.69% upside

Dividendos

By Acuity

Próximas Ganancias

4 nov 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

6.2B

45B

Apertura anterior

204.34

Cierre anterior

203.4

Noticias sobre sentimiento de mercado

By Acuity

76%

24%

308 / 339 Clasificación en Healthcare

REVOLUTION Medicines Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

11 sept 2026, 20:08 UTC

Revolution Medicines Inc shares are higher during Friday's session, despite earlier pulling back from an intraday high. No specific news was identified for the movement.

3 sept 2026, 19:16 UTC

News

Revolution Medicines Inc shares are higher after positive Phase 1/2 trial results for RASONQUE in advanced RAS mutant non-small cell lung cancer were published.

2 sept 2026, 23:51 UTC

News

Revolution Medicines shares rise in after-market trading following positive Phase 1/2 data on RASONQUE for advanced RAS mutant non-small cell lung cancer.

1 sept 2026, 23:06 UTC

Revolution Medicines Inc shares are higher in after-market trading, maintaining a stable performance since Tuesday's close despite earlier session volatility.

31 ago 2026, 20:07 UTC

Correlated Moves
News

Revolution Medicines Inc shares are lower amid broader market pressures and concerns from the Jackson Hole Economic Symposium regarding inflation and monetary policy tightening.

28 ago 2026, 20:02 UTC

Social Media
News

Revolution Medicines shares are lower amid significant selling pressure, despite recent price target increases by UBS and others for its drug RASONQUE.

27 ago 2026, 23:02 UTC

News

Revolution Medicines Inc shares are higher in after-market trading following FDA approval of RASONQUE for metastatic pancreatic cancer, discussed during an August 26 conference call.

26 ago 2026, 23:21 UTC

News
Social Media

Oppenheimer raised Revolution Medicines' price target to $260, citing FDA approval of RASONQUE for advanced pancreatic cancer, as shares trade higher in after-market hours.

25 ago 2026, 20:07 UTC

News

Revolution Medicines Inc received a "Moderate Buy" rating from brokerages. Needham raised its price target to $240, while shares are trading roughly flat.

24 ago 2026, 20:06 UTC

Revolution Medicines Inc shares are higher today, recovering from an earlier low. The stock has gained since Friday's close amid rising oil prices.

21 ago 2026, 19:46 UTC

News

Revolution Medicines shares are lower today as Bernstein raised its price target to $179, continuing a trend of three consecutive daily declines.

20 ago 2026, 23:26 UTC

Revolution Medicines Inc. shares were roughly flat in after-market hours, remaining above the 20-day moving average and near the upper end of their one-month range.

19 ago 2026, 19:46 UTC

News

Revolution Medicines Inc shares are lower Wednesday, pulling back after reaching a session high. The stock has declined since Tuesday's close.

17 ago 2026, 19:51 UTC

Social Media

Revolution Medicines shares are higher since Friday's close as Baker Bros boosts its stake to 11.4 million shares, valued at $2 billion.

13 ago 2026, 19:36 UTC

Revolution Medicines Inc shares are lower, reaching a session low earlier. This decline follows a cumulative drop since Wednesday's close.

12 ago 2026, 23:16 UTC

Revolution Medicines shares declined in after-market trading, despite earlier gains. The Consumer Price Index report showed a modest rise in consumer prices today.

11 ago 2026, 19:36 UTC

News

Revolution Medicines Inc is trading lower as broader geopolitical tensions and upcoming U.S. inflation reports weigh on market sentiment.

10 ago 2026, 23:51 UTC

Revolution Medicines Inc. shares were roughly flat in after-market hours, maintaining a position above the 20-day moving average and near the one-month range's upper end.

7 ago 2026, 19:11 UTC

News

Revolution Medicines Inc shares are higher as the company plans a Phase 3 study and Wedbush raises its price target to $201 from $192.

6 ago 2026, 19:36 UTC

Social Media
News

Revolution Medicines Inc is trading higher as RBC Capital and Evercore ISI raise price targets, reflecting growing confidence in the company's clinical pipeline.

5 ago 2026, 23:02 UTC

Social Media
News

Revolution Medicines shares lower in after-market trading following a second-quarter loss of $644.4 million and an EPS of -$3.06, missing estimates.

4 ago 2026, 23:06 UTC

Revolution Medicines shares are lower in after-market trading, settling near Tuesday's close. The stock remains above its 20-day moving average.

3 ago 2026, 23:26 UTC

Revolution Medicines Inc shares are trading higher in after-market hours. Broader market sentiment is positive, influenced by declining oil prices and reduced inflation concerns.

31 jul 2026, 20:06 UTC

Revolution Medicines Inc. shares are lower amid broader market volatility and rising U.S. Treasury yields, which have heightened inflation concerns and interest rate expectations.

30 jul 2026, 22:41 UTC

Revolution Medicines Inc. shares are lower in after-market trading, declining since Thursday's close amid fluctuations in bond yields and Fed policy uncertainty.

29 jul 2026, 17:02 UTC

Revolution Medicines Inc shares are lower, continuing a four-session decline with unusually high trading volume. The stock remains below its 20-day moving average.

28 jul 2026, 19:02 UTC

Revolution Medicines Inc shares are lower today, continuing a decline since Monday amid negative broader market sentiment following significant drops in Asian markets.

27 jul 2026, 20:06 UTC

Revolution Medicines Inc shares are lower amid broader market dynamics, including a decline in oil prices and falling Treasury yields ahead of the Federal Reserve meeting.

24 jul 2026, 18:26 UTC

Social Media
News

Revolution Medicines shares are lower amid broader market sentiment, despite RJ's increased price target of $230 and positive FDA news on daraxonrasib.

22 jul 2026, 18:26 UTC

Revolution Medicines Inc shares are higher today amid broader geopolitical tensions affecting market sentiment, despite no specific company news driving the movement.

Comparación entre iguales

Cambio de precio

REVOLUTION Medicines Inc previsión

Precio Objetivo

By TipRanks

23.69% repunte

Estimación a 12 Meses

Media 252.053 USD  23.69%

Máximo 320 USD

Mínimo 179 USD

De acuerdo con 21 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para REVOLUTION Medicines Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

21 ratings

20

Comprar

1

Mantener

0

Vender

Sentimiento

By Acuity

308 / 339 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura bajista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
help-icon Live chat